1-哌啶羧酰胺 | 4705-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-哌啶羧酰胺
• 英文名称: piperidine-1-carboxamidine
• 英文别名: N-amidinopiperidine；Piperidine-1-carboximidamide
• CAS: 4705-39-9
• 化学式: C₆H₁₃N₃
• mdl: MFCD05663370
• 分子量: 127.189
• InChiKey: QUUYRYYUKNNNNS-UHFFFAOYSA-N

物化性质

• 熔点：
  250-252 °C(Solv: ethanol (64-17-5))
• 沸点：
  202.9±23.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-哌啶羧酰胺 在 铁粉 、 potassium carbonate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 15.0h， 生成 2-(piperidin-1-yl)pyrimido[5,4-c]quinolin-5(6H)-one
  参考文献：
  名称：

  2,5-二取代嘧啶并[5,4-c]喹啉衍生物的合成及细胞毒活性

  摘要：

  摘要合成了2,5-二取代的嘧啶并[5,4-c]喹啉衍生物，并对其体外对H460，HT-29和MDA-MB-231细胞的杀伤活性进行了评价。发现大多数测试的化合物，特别是化合物17，对所选的三种细胞系显示出比ZM447439更强的活性。

  DOI：

  10.1016/j.cclet.2011.05.030
• 作为产物：
  描述：

  1H-1,2,4-三氮唑-1-甲脒单盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 哌啶 、 N,N-二甲基甲酰胺 为溶剂， 以82%的产率得到1-哌啶羧酰胺
  参考文献：
  名称：

  EP684227

  摘要：

  公开号：

文献信息

• Synthesis and antitumor activities of a new series of 4,5-dihydro-1H-thiochromeno[4,3-d]pyrimidine derivatives
  作者：DeXiang Guo、YaJing Liu、Ting Li、Nan Wang、Xin Zhai、Chun Hu、Ping Gong

  DOI：10.1007/s11426-011-4477-6

  日期：2012.3

  A new series of 4,5-dihydro-1H-thiochromeno[4,3-d]pyrimidine derivatives have been designed and synthesized. The antitumor activities of the target compounds have been evaluated in vitro against two human cancer cell lines including A549 (human alveolar adenocarcinoma cell) and H460 (human lung cancer) by MTT assay. Most of the target compounds exhibited significant antitumor activities against A549 and H460 cancer cell lines. The most potent compound 4-(benzo[d][1,3]dioxol-5-yl)-8,9-difluoro-2-(4-methylpiperazin-1-yl)-4,5-dihydro-1H-thiochromeno[4,3-d]pyrimidine (CH05) (IC50 = 0.44 μM, 3.07 μM) was 2.0 and 8.4 times more active than gefitinib (IC50 = 0.89 μM, 16.81 μM) against A549 and H460 cell lines, respectively.

  设计并合成了一系列4,5-二氢-1H-硫杂色满并[4,3-d]嘧啶衍生物。通过MTT法，在体外对两种人癌细胞系（包括A549（人肺泡腺癌细胞）和H460（人肺癌细胞））进行了目标化合物的抗肿瘤活性评估。大多数目标化合物对A549和H460癌细胞系表现出显著的抗肿瘤活性。其中最强效的化合物4-(苯并[d][1,3]二氧戊环-5-基)-8,9-二氟-2-(4-甲基哌嗪-1-基)-4,5-二氢-1H-硫杂色满并[4,3-d]嘧啶（CH05）（IC50 = 0.44 μM，3.07 μM）对A549和H460细胞系的活性分别是吉非替尼（IC50 = 0.89 μM，16.81 μM）的2.0倍和8.4倍。
• Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists
  作者：Natalie A. Hawryluk、Jeffrey E. Merit、Alec D. Lebsack、Bryan J. Branstetter、Michael D. Hack、Nadia Swanson、Hong Ao、Michael P. Maher、Anindya Bhattacharya、Qi Wang、Jamie M. Freedman、Brian P. Scott、Alan D. Wickenden、Sandra R. Chaplan、J. Guy Breitenbucher

  DOI：10.1016/j.bmcl.2010.09.023

  日期：2010.12

  Utilization of a tetrahydro-pyrimdoazepine core as a bioisosteric replacement for a piperazine-urea resulted in the discovery a novel series of potent antagonists of TRPV1. The tetrahydro-pyrimdoazepines have been identified as having good in vitro and in vivo potency and acceptable physical properties.

  利用四氢嘧啶并氮杂卓核作为哌嗪-尿素的生物等效替代物，导致发现了一系列新的TRPV1强效拮抗剂。已经确定四氢嘧啶并氮杂卓具有良好的体外和体内效力以及可接受的物理性质。
• [EN] 3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS<br/>[FR] CARBOXAMIDES DE 3,7-DIAZABICYCLO[3.3.1]NONANE À TITRE D'AGENTS ANTITHROMBOTIQUES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015044951A1

  公开（公告）日：2015-04-02

  The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

  本发明涉及3,7-二氮杂双环[3.3.1]壬烷羧酰胺及其制备方法。本发明还涉及具有抗血栓（抗血小板）活性的一般式（1）化合物。该发明还涉及将这些基团用作体外和体内介导的胶原受体抑制剂，抑制胶原诱导的血小板粘附和聚集。此外，该发明还涉及这类化合物通过双重机制表现出抗血小板功效，既抑制了胶原又抑制了U46619（血栓素受体激动剂）诱导的血小板聚集。一般式（1）中，其中，R'为；其中R选自烷基、酰基、对甲苯磺酰基、叔丁氧羰基、芳基烷基或取代芳基烷基；R''优选选自卤素、氰基、低烷基、芳基、取代芳基和对甲苯磺基；R1选自氢和低烷基；R2选自低烷基和芳基；R3选自叔丁氧羰基和苯甲氧羰基；n = 0,1。
• Photo- and dioxygen-enabled radical C(sp³)–N(sp²) cross-coupling between guanidines and perfluoroalkyl iodides
  作者：Shulin Liu、Rui Wang、Bo Zhu、Wei Guan、Fushun Liang

  DOI：10.1039/c9ob01520e

  日期：——

  A photo- and dioxygen-enabled intermolecular radical Csp3-Nsp2 cross-coupling between guanidines and perfluoroalkyl iodides has been developed. N2-Perfluoroalkacylguanidines, which are of biological importance, were obtained under mild conditions via Nsp2-perfluoroalkylation and subsequent hydrolysis. The role of dioxygen in the reaction system was tentatively elucidated; it was supposed to act as

  已经开发了在胍和全氟烷基碘之间具有光和双氧功能的分子间自由基Csp3-Nsp2交叉偶联。具有生物学重要性的N2-全氟烷基胍是在温和的条件下通过Nsp2-全氟烷基化和随后的水解而获得的。初步阐明了双氧在反应体系中的作用。它应该充当电子飞梭（氧化还原介体）。
• Amidination of Amines under Microwave Conditions Using Recyclable Polymer-Bound 1<i>H</i>-Pyrazole-1-carboxamidine
  作者：Andreas Kirschning、Wladimir Solodenko、Patrick Bröker、Josef Messinger、Uwe Schön

  DOI：10.1055/s-2006-926284

  日期：——

  A convenient one-step transformation of primary and secondary amines into the corresponding unprotected guanidines using 4-benzyl-3,5-dimethyl-1H-pyrazole-1-carboxamidine and its polymer-bound variant is described. The scopes and limitations of the method, the microwave-assistance of amidination as well as a recycling protocol are examined.

  报道了一种便捷的单步转化方法，可以将一级和二级胺转化为相应的无保护基胍化合物，所用试剂为4-苄基-3,5-二甲基-1H-吡唑-1-羰基氨脒及其聚合物衍生试剂。本文考察了该方法的应用范围和局限性、微波辅助酰胺化反应以及回收协议。